|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
SCIDIR_ocn644701406 |
| 003 |
OCoLC |
| 005 |
20231117033159.0 |
| 006 |
m o d |
| 007 |
cr bn||||||abp |
| 007 |
cr bn||||||ada |
| 008 |
100629s1989 caua ob 001 0 eng d |
| 040 |
|
|
|a OCLCE
|b eng
|e pn
|c OCLCE
|d OPELS
|d E7B
|d OCLCQ
|d IDEBK
|d OCLCF
|d UIU
|d N$T
|d YDXCP
|d OCLCQ
|d OCLCO
|d OCLCA
|d OCLCQ
|d OCLCA
|d LEAUB
|d OCLCO
|d LUN
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCL
|d OCLCO
|
| 019 |
|
|
|a 649706939
|a 974619777
|a 974665565
|
| 020 |
|
|
|a 9780323140485
|q (electronic bk.)
|
| 020 |
|
|
|a 0323140483
|q (electronic bk.)
|
| 020 |
|
|
|z 9780125440301
|
| 020 |
|
|
|z 0125440308
|q (alk. paper)
|
| 035 |
|
|
|a (OCoLC)644701406
|z (OCoLC)649706939
|z (OCoLC)974619777
|z (OCoLC)974665565
|
| 042 |
|
|
|a dlr
|
| 050 |
|
4 |
|a QP601.5
|b .E595 1989
|
| 060 |
|
4 |
|a QU 143
|b E6155 1989
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 615.7
|2 20
|
| 084 |
|
|
|a 44.38
|2 bcl
|
| 245 |
0 |
0 |
|a Enzymes as targets for drug design /
|c edited by Michael G. Palfreyman [and others].
|
| 260 |
|
|
|a San Diego :
|b Academic Press,
|c �1989.
|
| 300 |
|
|
|a 1 online resource (xiii, 267 pages) :
|b illustrations
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 506 |
|
|
|3 Use copy
|f Restrictions unspecified
|2 star
|5 MiAaHDL
|
| 533 |
|
|
|a Electronic reproduction.
|b [Place of publication not identified] :
|c HathiTrust Digital Library,
|d 2010.
|5 MiAaHDL
|
| 538 |
|
|
|a Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002.
|u http://purl.oclc.org/DLF/benchrepro0212
|5 MiAaHDL
|
| 583 |
1 |
|
|a digitized
|c 2010
|h HathiTrust Digital Library
|l committed to preserve
|2 pda
|5 MiAaHDL
|
| 588 |
0 |
|
|a Print version record.
|
| 650 |
|
0 |
|a Enzyme inhibitors.
|
| 650 |
|
0 |
|a Drugs
|x Design.
|
| 650 |
|
0 |
|a Enzymes.
|
| 650 |
|
2 |
|a Drug Design
|0 (DNLM)D015195
|
| 650 |
|
2 |
|a Enzyme Inhibitors
|x therapeutic use
|0 (DNLM)D004791Q000627
|
| 650 |
|
2 |
|a Enzyme Inhibitors
|0 (DNLM)D004791
|
| 650 |
|
2 |
|a Enzymes
|0 (DNLM)D004798
|
| 650 |
|
6 |
|a Enzymes.
|0 (CaQQLa)201-0002557
|
| 650 |
|
6 |
|a M�edicaments
|x Conception.
|0 (CaQQLa)201-0203461
|
| 650 |
|
6 |
|a Antienzymes.
|0 (CaQQLa)201-0014725
|
| 650 |
|
7 |
|a enzyme.
|2 aat
|0 (CStmoGRI)aat300212647
|
| 650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a Enzymes
|2 fast
|0 (OCoLC)fst00913605
|
| 650 |
|
7 |
|a Drugs
|x Design
|2 fast
|0 (OCoLC)fst00898790
|
| 650 |
|
7 |
|a Enzyme inhibitors
|2 fast
|0 (OCoLC)fst00913597
|
| 650 |
|
7 |
|a Enzyminhibitor
|2 gnd
|0 (DE-588)4152479-2
|
| 650 |
|
7 |
|a Arzneimittelentwicklung
|2 gnd
|0 (DE-588)4143176-5
|
| 650 |
|
7 |
|a Aufsatzsammlung
|2 gnd
|0 (DE-588)4143413-4
|
| 650 |
|
7 |
|a Arzneimittel
|2 gnd
|0 (DE-588)4003115-9
|
| 650 |
1 |
7 |
|a Enzymen.
|2 gtt
|
| 650 |
1 |
7 |
|a Geneesmiddelen.
|2 gtt
|
| 655 |
|
2 |
|a Congress
|0 (DNLM)D016423
|
| 655 |
|
7 |
|a proceedings (reports)
|2 aat
|0 (CStmoGRI)aatgf300027316
|
| 655 |
|
7 |
|a Conference papers and proceedings
|2 fast
|0 (OCoLC)fst01423772
|
| 655 |
|
7 |
|a Conference papers and proceedings.
|2 lcgft
|
| 655 |
|
7 |
|a Actes de congr�es.
|2 rvmgf
|0 (CaQQLa)RVMGF-000001049
|
| 700 |
1 |
|
|a Palfreyman, Michael G.
|
| 776 |
0 |
8 |
|i Print version:
|w (DLC) 89018313
|w (OCoLC)20669818
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780125440301
|z Texto completo
|
